Memphis-based US Biologic receives funding to develop orally administered flu vaccine

“The way we are producing vaccines — making them orally available, reducing production costs, and increasing shelf life — we are increasing health care equity.”
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.